Trial Profile
An Open-Label, Randomized Crossover Study to Evaluate the Acceptability and Preference for Contraceptive Options in Healthy HIV-Uninfected Female Adolescents, 16-17 Years of Age, as Proxy for HIV Prevention Methods
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs Ethinylestradiol/etonogestrel (Primary) ; Ethinylestradiol/etonogestrel (Primary) ; Ethinylestradiol/levonorgestrel (Primary) ; Norethisterone enantate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms UChoose
- 02 Nov 2019 Results published in the Clinical Infectious Diseases
- 21 Jul 2017 Planned End Date changed from 1 Feb 2016 to 1 Feb 2018.
- 21 Jul 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2017.